Recent Release | 13 Jul 2020

Trade and transport margins in pharmaceuticals and other R&D-intensive industries

trade-and-transport-margins-in-pharmaceuticals-and-other-r-and-d-intensive-industries-300px

Spending for prescription and over-the-counter pharmaceutical products totaled $413 billion in 2012 according to the Bureau of Economic Analysis’ (BEA) trade and transports margin data. Just over half of this spending (52%) accrued to the pharmaceutical companies that produced the medicines, while the remainder was divided between transport and wholesale margins (21%) and retail margins (26%).

Compared to other research and development (R&D)-intensive manufacturing industries with significant consumer sales, the pharmaceutical and medicines manufacturing industry ranks second in terms of R&D intensity behind communications equipment, and receives the second lowest producers’ share of total spending after other miscellaneous manufacturing. Thus, the pharmaceutical industry is unique among manufacturing industries in that it devotes a large share of its revenue to R&D, despite receiving a considerably smaller share of total spending.

Read the report

You may be interested in

Commodities trading

Post

Oxford Economics enhances its Commodity Price Forecasts coverage

Oxford Economics expands Commodity Price Forecasts service to include battery metals, agricultural commodities and plastics.

Find Out More

Post

Oxford Economics Expands Regional Presence with the Launch of Chinese Website

Over the past six years we've maintained the unique modelling and analysis that clients and the media have come to rely on from BIS Shrapnel while incorporating Oxford Economics' rigorous global modelling and analytical framework to complement it," said David Walker, Director, Oxford Economics Australia.

Find Out More

Post

Oxford Economics Introduces Proprietary Data Service

Oxford Economics is excited to enrich its suite of asset management solutions with the introduction of the Proprietary Data Service.

Find Out More